Tirzepatide vs. semaglutide: what the head-to-head data actually shows

What did @andresgimenez.obesidad actually say?

Here is the uncomfortable truth about this fact-check: the transcript provided does not match the video caption at all. The caption promises a comparison of tirzepatide and semaglutide, two of the most-discussed GLP-1 related medications in obesity medicine. But the transcript itself is incoherent text that appears to be a transcription error, auto-caption glitch, or mislabeled audio. It contains no medical claims whatsoever.

What we can evaluate is the caption's written claims: that semaglutide was "the pioneer" in this drug class, that it showed weight reduction and improved glucose control, and that tirzepatide "acts in two" receptors (the caption cuts off). These are substantive medical claims worth examining on their own merits, even if the spoken transcript cannot be verified here.

We are flagging this transcript issue directly. Any fact-check based on this audio would be fabricated. We are working from the caption only.

Does the science back up the caption's claims?

Largely, yes. Semaglutide's evidence base is genuinely strong, and calling it a pioneer in this class is defensible. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 14.9% mean body weight reduction with once-weekly semaglutide 2.4mg versus 2.4% with placebo in adults with obesity. That was a landmark result. Tirzepatide's dual receptor mechanism is also real science.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15mg achieving up to 20.9% mean body weight reduction, outperforming semaglutide in head-to-head modeling. The SURPASS-2 trial (Frías et al., 2021, New England Journal of Medicine) directly compared tirzepatide to semaglutide in type 2 diabetes and found tirzepatide superior on both HbA1c reduction and weight loss. So the implication that tirzepatide may be more effective is supported by current data.

What did the caption get wrong or right?

The caption gets the basic narrative right. Semaglutide did come first in clinical adoption for obesity, and tirzepatide does act on two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Calling semaglutide "the pioneer" is fair, though liraglutide (Victoza, Saxenda) preceded it in both diabetes and obesity indications and deserves a mention for accuracy.

What the caption leaves out matters. Neither drug cures obesity or diabetes. Both require ongoing use to maintain results. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) showed semaglutide reduced major cardiovascular events by 20% in people with obesity and established cardiovascular disease, a benefit not yet fully established for tirzepatide. Tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is still ongoing as of 2024. Framing tirzepatide as simply "better" ignores that the cardiovascular evidence is not yet equivalent.

What should you actually know?

Both drugs are effective. The question of which is "better" depends entirely on the individual patient, their comorbidities, insurance coverage, tolerance of side effects, and treatment goals. That is not a hedge. It is the clinical reality.

Tirzepatide's weight loss numbers are currently larger in trials, but larger weight loss does not automatically mean better health outcomes for every patient. Side effect profiles are similar, with nausea, vomiting, and gastrointestinal symptoms common to both. Neither drug should be started, stopped, or switched without physician oversight.

Compounded versions of both drugs exist in the market and are not equivalent to FDA-approved branded formulations. Patients seeing content like this should bring questions to a licensed provider, not make medication decisions based on social media captions.